newsfilter
← Latest News
GlobeNewswire·

Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences

  • Silexion Therapeutics Corp (NASDAQ: SLXN) announced its management team will attend three industry & investor conferences in September 2026.
  • Dr. Mitchell Shirvan, Chief Scientific & Development Officer, will present at the Oncology & Immunology Innovation Partnering & Licensing Summit on September 9, 2026, in Boston, MA.
  • Dr. Mitchell Shirvan will also present at the 8th Annual RAS-Targeted Drug Development Summit on September 10, 2026, in Boston, MA.
  • CEO Ilan Hadar & CFO Mirit Horenshtein Hadar will hold one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference from September 14–16, 2026, in New York, NY.
  • The Company is developing SIL204, an investigational pan-KRAS RNA interference therapy, within an ongoing Phase 2/3 clinical program for locally advanced pancreatic cancer.
  • Silexion previously conducted a Phase 2a trial of its first-generation product candidate which showed a positive trend versus chemotherapy alone.
  • The press release includes forward-looking statements regarding clinical trial success, financial stability, regulatory compliance, partnership potential, capital requirements, listing maintenance, & going concern risks.